Anvisa approves expanded pediatric indications for belimumab and ocrelizumab

Brazil's health regulator, Anvisa, has authorized the use of belimumab for pediatric lupus patients aged five and older, and ocrelizumab for pediatric multiple sclerosis patients aged 12 and older. This regulatory expansion increases treatment options for chronic autoimmune conditions in the pediatric population.